Published on investors chronicle: 22nd July, 2019

Author: Simon Thompson

IXICO may be a small-cap London-based company well under the radar of investors, but it is highly regarded by pharmaceutical and biotechnology companies and huge corporations are increasingly awarding the company new contracts. In fact, IXICO has booked over £20m worth of new orders since the start of last year, a revenue stream that underpins a move to operating profitability. Once that inflexion point is passed, the high gross margin earned from its cutting-edge data analytics activities means operating profits are set to move sharply higher in the years ahead, a point that is not factored into a valuation of little over one times the company’s enterprise value to forecast sales in the 2021 financial year.

View the full report here; https://pdfs.investorschronicle.co.uk/IC_Alpha_IXICO_Simon_2207.pdf

---